HerediGENE Gene Panel

brca gene mutation

The table below lists genes analyzed by the HerediGene assay known for common cancer syndromes (such as BRCA1 and BRCA2 gene mutations for Hereditary breast and ovarian cancer  and Fanconi anaemia FA-D1 – BRCA2) and common types of cancer.

Genes for hereditary cancer:

-Colon Cancer such as APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, POLE, POLD1 and SMAD4 genes.

-Breast Cancer genes such as ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK1, CHEK2, FANCA, FANCM, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51B, RAD51C, RAD51, RAD51.

-Pancreatic Cancer genes such as ATM, BRCA1, BRCA2, CDKN2A, FANCA, FANCM, MEN1, MLH1, MSH2, (MSH6), PALB2 and STK11 genes

-Ovarian Cancer genes  BARD1, BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, MSH6, RAD51C, RAD51D and TP53

-Gastric Cancer genes CDH1 and FANCA.

-Melanoma genes such as CDK4, CDKN2A, PTEN and TP53.

-Endometrial Cancer genes such as EPCAM, FANCA and MLH1.

-Endocrine Cancer genes (Familial Adenomatous Polyposis, Multiple endocrine neoplasia Type 1) such as APC, MEN1, RET and VHL.

-Prostate Cancer genes such as ATM, BRCA1, BRCA2, CHEK2, HOXB13, MLH1, MSH2, MSH6, PALB2 and PMS2.

-For Lynch syndrome such as EPCAM, MLH1, MSH2, MSH6 and PMS2.

Table of GENES

gene panel

The latest international guidelines (ASCO, ESMO, NCCN and American Society of Breast Surgeons) strongly recommend, instead of BRCA1/2 only, the use of multi-gene panels for a better coverage of the gene variants associated with an increased risk of breast, prostate, colon, pancreatic, ovarian cancer etc.